1. Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte-stimulating hormone.
2. Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats.
3. AP214, an analogue of α-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality
4. AP214 improves long-term (3 month) outcome on composite endpoint of death, renal replacement therapy or reduced kidney function in patients undergoing cardiac surgery in a phase 2 clinical trial;Steinbruchel;Clin J Am Soc Nephrol,2011
5. ClinicalTrials.gov: A safety and efficacy trial of multiple dosing regimens of ABT-719 for the prevention of acute kidney injury in subjects undergoing high risk cardiac surgery. NCT01777165 Jan 24, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01777165. Accessed February 1, 2013